

# Benny V Jensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8310033/publications.pdf>

Version: 2024-02-01

64  
papers

3,812  
citations

279487

23  
h-index

143772

57  
g-index

64  
all docs

64  
docs citations

64  
times ranked

5576  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2207-2218.	13.9	1,513
2	MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 392.	3.8	380
3	Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 15-21.	0.8	298
4	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 659-670.	5.1	282
5	Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA4-LBA4.	0.8	150
6	High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4423-34.	3.2	123
7	Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 665-677.	5.1	110
8	Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055.	1.9	73
9	miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan. <i>PLoS ONE</i> , 2014, 9, e99886.	1.1	68
10	A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan + targeted therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 701-715.	3.4	64
11	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	1.7	63
12	Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685.	1.3	48
13	Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. <i>International Journal of Cancer</i> , 2020, 146, 2913-2922.	2.3	41
14	Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab. <i>PLoS ONE</i> , 2014, 9, e109430.	1.1	39
15	A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. <i>Acta Oncologica</i> , 2019, 58, 1149-1157.	0.8	34
16	Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. <i>Acta Oncologica</i> , 2007, 46, 697-701.	0.8	33
17	The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. <i>International Journal of Cancer</i> , 2016, 139, 2312-2324.	2.3	33
18	Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). <i>Journal of Clinical Oncology</i> , 2022, 40, 3180-3189.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 97769-97786.	0.8	28
20	MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability. <i>BMC Cancer</i> , 2015, 15, 1024.	1.1	27
21	Improved survival with early adjuvant chemotherapy after colonic resection for stage III colonic cancer: A nationwide study. <i>Journal of Surgical Oncology</i> , 2015, 112, 538-543.	0.8	27
22	Risk factors for brain metastases in patients with metastatic colorectal cancer. <i>Acta Oncologica</i> , 2017, 56, 639-645.	0.8	26
23	Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. <i>British Journal of Cancer</i> , 2018, 118, 1322-1328.	2.9	26
24	Associations between primary tumor <i>RAS</i> , <i>BRAF</i> and <i>PIK3CA</i> mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. <i>Acta Oncologica</i> , 2018, 57, 1057-1062.	0.8	24
25	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015, 64, 921-928.	6.1	22
26	Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.. <i>Acta Oncologica</i> , 2006, 45, 1137-1138.	0.8	19
27	The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. <i>Acta Oncologica</i> , 2019, 58, 864-871.	0.8	19
28	Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13219.	0.7	19
29	Observer variability in a phase II trial " assessing consistency in RECIST application. <i>Acta Oncologica</i> , 2012, 51, 774-780.	0.8	17
30	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. <i>BMC Cancer</i> , 2017, 17, 48.	1.1	17
31	Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. <i>European Journal of Cancer</i> , 2021, 144, 72-80.	1.3	17
32	Seeding after ultrasound-guided percutaneous biopsy of liver metastases in patients with colorectal or breast cancer. <i>Acta Oncologica</i> , 2016, 55, 638-643.	0.8	16
33	Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8 years of follow-up. <i>International Journal of Cancer</i> , 2020, 146, 2019-2026.	2.3	14
34	Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. <i>Clinical Cancer Research</i> , 2021, 27, 2592-2603.	3.2	14
35	Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 176-184.	1.1	12
36	Increased prognostic value of combined myocardial perfusion imaging and exercise electrocardiography in patients with coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 616-622.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e7-e14.	1.0	10
38	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881120.	0.8	10
39	Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis. <i>Cancers</i> , 2022, 14, 161.	1.7	9
40	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5027.	1.8	7
41	Prognostic and predictive value of circulating DNA for hepatic arterial infusion of chemotherapy for patients with colorectal cancer liver metastases. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	6
42	Early <sup>18</sup> F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab. <i>Acta Oncologica</i> , 2016, 55, 1175-1182.	0.8	4
43	Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. <i>International Journal of Cancer</i> , 2021, 148, 2542-2556.	2.3	4
44	Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma – An external validation study. <i>Pancreatology</i> , 2021, 21, 1081-1091.	0.5	4
45	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. <i>Cancers</i> , 2022, 14, 3250.	1.7	4
46	An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 441-446.	1.1	3
47	Intrahepatic Oxaliplatin and Systemic 5-FU + Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer. <i>Oncology</i> , 2019, 96, 299-308.	0.9	2
48	Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3572-3572.	0.8	2
49	Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 288-288.	0.8	2
50	MicroRNA biomarkers in whole blood for detection of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4052-4052.	0.8	2
51	A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). <i>Pharmaceutics</i> , 2022, 14, 509.	2.0	2
52	Impact of microRNA miR-345 in blood on survival and response in 144 patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012, 30, 451-451.	0.8	1
53	The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15131-e15131.	0.8	1
54	Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 164-164.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.. Journal of Clinical Oncology, 2015, 33, 4022-4022.	0.8	1
56	Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.. Journal of Clinical Oncology, 2018, 36, e16249-e16249.	0.8	1
57	Randomized phase 2 study of nivolumab with or without ipilimumab in combination with stereotactic body radiotherapy in patients with refractory metastatic pancreatic cancer (CHECKPAC).. Journal of Clinical Oncology, 2022, 40, 554-554.	0.8	1
58	Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. European Journal of Cancer, 2021, 158, 248-250.	1.3	0
59	Diagnostic microRNA serum profile in pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 160-160.	0.8	0
60	Oxaliplatin given by hepatic arterial infusion (HAI) or systemic (SYS) with capecitabine in patients (pts) with unresectable liverlimited metastasis (Ur-LLM) from colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, e14593-e14593.	0.8	0
61	Seeding after biopsy of liver metastases in patients with primary colorectal and breast cancer.. Journal of Clinical Oncology, 2014, 32, e14545-e14545.	0.8	0
62	Outcome of cetuximab plus irinotecan in relation to <i>RAS</i> and <i>BRAF</i> mutational status in patients with colorectal cancer prior treated with a fluoropyrimidine, oxaliplatin and irinotecan.. Journal of Clinical Oncology, 2016, 34, e15115-e15115.	0.8	0
63	The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15060-e15060.	0.8	0
64	Prognostic value of serum interleukin-6 and YKL-40 and systemic inflammatory response in patients with unresectable pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, 267-267.	0.8	0